Premium
CAR chasing: canine adenovirus vectors–all bite and no bark?
Author(s) -
Kremer Eric J.
Publication year - 2004
Publication title -
the journal of gene medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.689
H-Index - 91
eISSN - 1521-2254
pISSN - 1099-498X
DOI - 10.1002/jgm.497
Subject(s) - tropism , neuroscience , genetic enhancement , amyotrophic lateral sclerosis , viral vector , vector (molecular biology) , biology , axoplasmic transport , central nervous system , virology , immunology , multiple sclerosis , gene transfer , immune system , medicine , gene , pathology , virus , disease , genetics , recombinant dna
This review deals primarily with canine adenovirus serotype 2 (CAV‐2) vectors and gives a simplified overview of how the various domains of virology, cellular and molecular biology, as well as immunology, come into play when trying to understand and ameliorate adenovirus (Ad)‐mediated gene transfer. The generation of early region 1 (E1)‐deleted (ΔE1) CAV‐2 vectors, the lack of pre‐existing humoral immunity, trafficking, the use of the coxsackie B adenovirus receptor (CAR), the surprising neuronal tropism, and the ability to migrate via axons to afferent regions of the central and peripheral nervous system, are described. Due to these intrinsic properties, CAV‐2 vectors may be powerful tools for the study of the pathophysiology and potential treatment of neurodegenerative diseases like lysosomal storage disorders, Parkinson's, Alzheimer's, Huntington's, amyotrophic lateral sclerosis, and others. Other potential uses include anti‐tumoral and anti‐viral vaccines, tracer of synaptic junctions, pain therapy, cancer therapy (e.g. K9 CRAds), and gene transfer to other somatic tissues. Copyright © 2004 John Wiley & Sons, Ltd.